Trial of Nivolumab With Chemotherapy as Neoadjuvant Treatment in Inflammatory Breast Cancer (IBC)

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

8 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-05-02

Study Completion Date

2023-06-12

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Study of efficacy of nivolumab with neoadjuvant chemotherapy in patients with IBC

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Pre-operative Trial for Breast Cancer With Nivolumab in Combination With Novel IO

NCT03815890

Breast Cancer

RECRUITING PHASE2

Entinostat, Nivolumab, and Ipilimumab in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Locally Advanced or Metastatic HER2-Negative Breast Cancer

NCT02453620

Anatomic Stage III Breast Cancer AJCC v8 Anatomic Stage IV Breast Cancer AJCC v8 Breast Adenocarcinoma +2 more

ACTIVE_NOT_RECRUITING PHASE1

Trial of Ibrutinib Plus Trastuzumab in HER2-amplified Metastatic Breast Cancer

NCT03379428

Breast Neoplasms Malignant Neoplasm of Breast

ACTIVE_NOT_RECRUITING PHASE1/PHASE2

Pembrolizumab in Treating Patients With Hormone Receptor Positive, Localized Inflammatory Breast Cancer Who Are Receiving Hormone Therapy and Did Not Achieve a Pathological Complete Response to Chemotherapy

NCT02971748

Anatomic Stage IIIB Breast Cancer AJCC v8 Anatomic Stage IIIC Breast Cancer AJCC v8 Breast Inflammatory Carcinoma +2 more

ACTIVE_NOT_RECRUITING PHASE2

BMS-986156, Ipilimumab, and Nivolumab With or Without Stereotactic Body Radiation Therapy in Treating Patients With Advanced or Metastatic Lung/Chest or Liver Cancers

NCT04021043

Advanced Malignant Solid Neoplasm Metastatic Carcinoma in the Liver Metastatic Carcinoma in the Lung +2 more

COMPLETED PHASE1/PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The purpose of this study is to determine whether the addition of nivolumab to chemotherapy improves pathologic complete response (pCR) in the breast and post-therapy lymph nodes evaluated histologically (ypT0/Tis ypN0) in patients with inflammatory breast cancer (IBC).

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Breast Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

HER2-negative, including TNBC or HR-positive

Group Type EXPERIMENTAL

Nivolumab 360mg

Intervention Type DRUG

Nivolumab 360 mg IV on Day 1 of every 21 day cycle (Cycle 1-4)

Paclitaxel 80mg/m^2

Intervention Type DRUG

Paclitaxel 80mg/m\^2 IV on Day of 1, 8, 15 of every 21 day cycle (Cycle 1-4)

Doxorubicin 60mg/m^2

Intervention Type DRUG

Doxorubicin 60 mg/m\^2 IV on Day 1 of every 14 day cycle (Cycle 5-8)

Cyclophosphamide 600mg/m^2

Intervention Type DRUG

Cyclophosphamide 600mg/m\^2 on Day 1 of every 14 day cycle (Cycle 5-8)

HER2-positive, independent of HR status

Group Type EXPERIMENTAL

Nivolumab 360mg

Intervention Type DRUG

Nivolumab 360 mg IV on Day 1 of every 21 day cycle (Cycle 1-4)

Doxorubicin 60mg/m^2

Intervention Type DRUG

Doxorubicin 60 mg/m\^2 IV on Day 1 of every 14 day cycle (Cycle 5-8)

Cyclophosphamide 600mg/m^2

Intervention Type DRUG

Cyclophosphamide 600mg/m\^2 on Day 1 of every 14 day cycle (Cycle 5-8)

Paclitaxel 80mg/m^2 or Docetaxel 75mg/m^2

Intervention Type DRUG

Paclitaxel 80mg/m\^2 on Day 1, 8, 15 of every 21 day cycle (Cycle 1-4) OR Docetaxel 75mg/m\^2 on Day 1 of every 21 day cycle (Cycle 1-4)

Trastuzumab 8mg/kg and 6 mg/kg

Intervention Type DRUG

Trastuzumab 8mg/kg IV on Day 1 of Cycle 1 and then 6mg/kg IV on Day 1 of Cycle 2-4

Pertuzumab 840mg and 420mg

Intervention Type DRUG

Pertuzumab 840mg on Day 1 of Cycle 1 and then 420mg IV on Day 1 of Cycle 2-4

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Nivolumab 360mg

Nivolumab 360 mg IV on Day 1 of every 21 day cycle (Cycle 1-4)

Intervention Type DRUG

Paclitaxel 80mg/m^2

Paclitaxel 80mg/m\^2 IV on Day of 1, 8, 15 of every 21 day cycle (Cycle 1-4)

Intervention Type DRUG

Doxorubicin 60mg/m^2

Doxorubicin 60 mg/m\^2 IV on Day 1 of every 14 day cycle (Cycle 5-8)

Intervention Type DRUG

Cyclophosphamide 600mg/m^2

Cyclophosphamide 600mg/m\^2 on Day 1 of every 14 day cycle (Cycle 5-8)

Intervention Type DRUG

Paclitaxel 80mg/m^2 or Docetaxel 75mg/m^2

Paclitaxel 80mg/m\^2 on Day 1, 8, 15 of every 21 day cycle (Cycle 1-4) OR Docetaxel 75mg/m\^2 on Day 1 of every 21 day cycle (Cycle 1-4)

Intervention Type DRUG

Trastuzumab 8mg/kg and 6 mg/kg

Trastuzumab 8mg/kg IV on Day 1 of Cycle 1 and then 6mg/kg IV on Day 1 of Cycle 2-4

Intervention Type DRUG

Pertuzumab 840mg and 420mg

Pertuzumab 840mg on Day 1 of Cycle 1 and then 420mg IV on Day 1 of Cycle 2-4

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Newly diagnosed inflammatory breast cancer without distant metastases and have not received prior chemotherapy or immunotherapy. All breast cancer subtypes are allowed: Triple negative breast cancer (TNBC); Hormone receptor (HR)-positive and human epidermal growth factor receptor 2 (HER2)-negative; HR-positive or HR-negative and HER2-positive

Exclusion Criteria

* Clinical or radiologic evidence of distant metastases
* Malignancy that progressed within the last five years.
* Cardiac disease (history of and/or active disease)
* HIV positive
* Neuropathy ≥ Grade 2, per the NCI CTCAE v5.0
* Allogeneic stem cell or solid organ transplantation
* Autoimmune disease where in the opinion of the Investigator would preclude the use of immunotherapy
* Idiopathic pulmonary fibrosis, organizing pneumonia (e.g., bronchiolitis obliterans), or evidence of active pneumonitis
* Tuberculosis
* Pregnancy or lactation
* Treatment with CD137 agonists or immune checkpoint-blockade therapies, including anti-CD40, anti-CTLA-4, anti-PD-1, and anti-PD-L1 therapeutic antibodies
* Treatment with systemic immunosuppressive medications
* Cardiopulmonary dysfunction
* Clinically significant history of liver disease, including cirrhosis, autoimmune hepatic disorders, HIV infection, or active Hepatitis B or Hepatitis C
* Subject is pregnant or nursing
* Known hypersensitivity to the components of the study drugs(s)

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No